Stock Market News
Avacta reaches licensing agreement with Glythera after initial study yields positive results
Biotechnology company Avacta Group has successfully concluded its initial study with next-generation antibody drug conjugates developer Glythera, leading to a licensing agreement between the two firms.
While detailed terms of the license between the two had not been made available, it was revealed that Avacta would receive development milestone payments and royalties on sales of an approved drug developed by Glythera.
Initial trials showed that Avacta's Affirmer technology could be combined with Glythera's Permalink conjugation chemistry to provide a "technologically superior drug conjugate platform" that had shorter development times, simpler, more consistent production and greater chemical stability than competitors.
Evidence that Affirmer remained functional when the toxic payload had been added also indicated that when combined, the two technologies held the potential to develop drug conjugate therapies.
Dr Alastair Smith, Avacta Group chief executive officer, said, "The drug conjugate market is a very important one for the Affimer technology because of the key benefits of Affimers' solvent stability, controlled conjugation chemistry and small size which have now been clearly demonstrated. When combined with the benefits of Glythera's Permalink chemistry, we believe that there is potential to create a competitive, differentiated drug conjugate platform."
"I am delighted with the reciprocal arrangements that we have put in place with Glythera allowing both companies to develop Affimer-Permalink drug conjugates and I look forward to updating the market on progress in Avacta's drug development programmes in due course," Smith added.
As of 1330 GMT, shares had edged up 2.37% to 67.05p.
While detailed terms of the license between the two had not been made available, it was revealed that Avacta would receive development milestone payments and royalties on sales of an approved drug developed by Glythera.
Initial trials showed that Avacta's Affirmer technology could be combined with Glythera's Permalink conjugation chemistry to provide a "technologically superior drug conjugate platform" that had shorter development times, simpler, more consistent production and greater chemical stability than competitors.
Evidence that Affirmer remained functional when the toxic payload had been added also indicated that when combined, the two technologies held the potential to develop drug conjugate therapies.
Dr Alastair Smith, Avacta Group chief executive officer, said, "The drug conjugate market is a very important one for the Affimer technology because of the key benefits of Affimers' solvent stability, controlled conjugation chemistry and small size which have now been clearly demonstrated. When combined with the benefits of Glythera's Permalink chemistry, we believe that there is potential to create a competitive, differentiated drug conjugate platform."
"I am delighted with the reciprocal arrangements that we have put in place with Glythera allowing both companies to develop Affimer-Permalink drug conjugates and I look forward to updating the market on progress in Avacta's drug development programmes in due course," Smith added.
As of 1330 GMT, shares had edged up 2.37% to 67.05p.
Related share prices |
---|
Avacta Group (AVCT) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price